Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 8, 2008 - Issue 7
Submit an article Journal homepage
449
Views
52
CrossRef citations to date
0
Altmetric
Reviews

Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease

Vincent G Brichard GlaxoSmithKline Biologicals, Cancer Immunotherapeutics R&D, Rue de l'Institut, 89, B-1330 Rixensart, Belgium +32 2 656 62 11; +32 2 656 90 49; [email protected]
&
Diane Lejeune GlaxoSmithKline Biologicals, Cancer Immunotherapeutics R&D, Rue de l'Institut, 89, B-1330 Rixensart, Belgium +32 2 656 62 11; +32 2 656 90 49; [email protected]
Pages 951-968 | Published online: 12 Jun 2008

Bibliography

  • Nauts HC. Bacteria and cancer – antagonisms and benefits. Cancer Surv 1989;8(4):713-23
  • Jaffee EM, Pardoll DM. Murine tumor antigens: is it worth the search? Curr Opin Immunol 1996;8(5):622-7
  • Papac DI, Briggs JB, Chin ET, Jones AJ. A high-throughput microscale method to release N-linked oligosaccharides from glycoproteins for matrix-assisted laser desorption/ionization time-of-flight mass spectrometric analysis. Glycobiology 1998;8(5):445-54
  • McCann J. Can skin cancers be minimized or prevented in organ transplant patients? J Natl Cancer Inst 1999;91(11):911-3
  • Parmiani G, Anichini A, Fossati G. Cellular immune response against autologous human malignant melanoma: are in vitro studies providing a framework for a more effective immunotherapy? J Natl Cancer Inst 1990;82(5):361-70
  • Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994;86(15):1159-66
  • Shen X, Zhou J, Hathcock KS, et al. Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length. J Immunother 1997;30(1):123-9
  • Gale RP, Champlin RE. How does bone-marrow transplantation cure leukaemia? Lancet 1984;2(8393):28-30
  • Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75(3):555-62
  • Truitt RL, Johnson BD. Principles of graft-vs.-leukemia reactivity. Biol Blood Marrow Transplant 1995;1(2):61-8
  • Weiden PL, Sullivan KM, Flournoy N, et al. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981;304(25):1529-33
  • Van Pel A, Boon T. Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc Natl Acad Sci USA 1982;79(15):4718-22
  • Levy F, Colombetti S. Promises and limitations of murine models in the development of anticancer T-cell vaccines. Int Rev Immunol 2006;25(5-6):269-95
  • Copier J, Dalgleish A. Overview of tumor cell-based vaccines. Int Rev Immunol 2006;25(5-6):297-319
  • Uyl-De Groot CA, Vermorken JB, Hanna MG Jr, et al. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. Vaccine 2005;23(17-18):2379-87
  • Motl SE. Technology evaluation: Canvaxin, John Wayne Cancer Institute/CancerVax. Curr Opin Mol Ther 2004;6(1):104-11
  • Kelland L. Discontinued drugs in 2005: oncology drugs. Expert Opin Investig Drugs 2006;15(11):1309-18
  • Hege KM, Jooss K, Pardoll D. GM-CSF gene-modifed cancer cell immunotherapies: of mice and men. Int Rev Immunol 2006;25(5-6):321-52
  • ClinicalTrials.gov. Clinical trials registry. Available from: http://www.ClinicalTrials.gov
  • Sondak VK, Sosman JA. Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine. Semin Cancer Biol 2003;13(6):409-15
  • Sondak VK, Sosman J, Unger JM, et al. Significant impact of HLA class I allele expression on outcome in melanoma patients treated with an allogeneic melanoma cell lysate vaccine. Final analysis of SWOG-9035. ASCO Annual Meeting Proceedings Part. J Clin Oncol 2004;22(14S Suppl):7501
  • Jocham D, Richter A, Hoffmann L, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004;363(9409):594-9
  • Srivastava PK, Deleo AB, Old LJ. Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc Natl Acad Sci USA 1986;83(10):3407-11
  • Binder RJ. Heat shock protein vaccines: from bench to bedside. Int Rev Immunol 2006;25(5-6):353-75
  • Oki Y, McLaughlin P, Fayad LE, et al. Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. Cancer 2007;109(1):77-83
  • Lee KP, Raez LE, Podack ER. Heat shock protein-based cancer vaccines. Hematol Oncol Clin North Am 2006;20(3):637-59
  • Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Ann Rev Immunol 2001;19:225-52
  • Takahashi T, Tagami T, Yamazaki S, et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000;192(2):303-10
  • Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity 1997;7(4):445-50
  • Maker AV, Yang JC, Sherry RM, et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother 2006;29(4):455-63
  • Maker AV, Phan GQ, Attia P, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 2005;12(12):1005-16
  • Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006;24(15):2283-9
  • Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 2005;23(35):8968-77
  • Ribas A, Bozon VA, Lopez-Berestein G, et al. Phase 1 trial of monthly doses of the human anti-CTLA4 monoclonal antibody CP-675,206 in patients with advanced melanoma. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2005;23(16S Suppl):7524
  • Ribas A, Comin-Anduix B, Bozon V, et al. Antigen-specific T cell responses in patients with melanoma traeted with the CTLA4 blocking mAb CP-675,206. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006;24(18S Suppl):8033
  • Langer LF, Clay TM, Morse MA. Update on anti-CTLA-4 antibodies in clinical trials. Expert Opin Biol Ther 2007;7(8):1245-56
  • Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8(8):793-800
  • Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192(7):1027-34
  • Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002;99(19):12293-7
  • Belardelli F, Ferrantini M, Proietti E, Kirkwood JM. Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002;13(2):119-34
  • Eggermont AM. Critical appraisal of IFN-alpha-based adjuvant therapy in stage II – III malignant melanoma. Expert Rev Anticancer Ther 2002;2(5):563-9
  • Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14(1):7-17
  • Grob JJ, Dreno B, De La SP, et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 1998;351(9120):1905-10
  • Gogas H, Dafni U, Bafaloukos D, et al. A randomized phase III trial of 1 month versus 1 year adjuvant high-dose interferon alpha-2b in patients with resected high risk melanoma. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S Suppl):8505
  • Bukowski RM, Tendler C, Cutler D, et al. Treating cancer with PEG intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation. Cancer 2002;95(2):389-96
  • Delgado C, Francis GE, Fisher D. The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst 1992;9(3-4):249-304
  • Inada Y, Furukawa M, Sasaki H, et al. Biomedical and biotechnological applications of PEG- and PM-modified proteins. Trends Biotechnol 1995;13(3):86-91
  • Eggermont AM, Suciu S, Santinami M, et al. EORTC 18991: Long-term adjuvant pegylated interferon-alpha2b (PEG-IFN) compared to observation in resected stage III melanoma, final results of a randomized phase III trial. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S Suppl):8504
  • Kleinerman ES, Kurzrock R, Wyatt D, et al. Activation or suppression of the tumoricidal properties of monocytes from cancer patients following treatment with human recombinant gamma-interferon. Cancer Res 1986;46(10):5401-5
  • Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006;6(11):836-48
  • Kleeberg UR, Suciu S, Brocker EB, et al. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer 2004;40(3):390-402
  • Rosenberg SA, Mule JJ, Spiess PJ, et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 1985;161(5):1169-88
  • Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17(7):2105-16
  • Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13(3):688-96
  • Markovic SN, Erickson LA, Rao RD, et al. Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment. Mayo Clin Proc 2007;82(4):490-513
  • Hauschild A, Garbe C, Stolz W, et al. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG). Br J Cancer 2001;84(8):1036-42
  • Huncharek M, Caubet JF, McGarry R. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res 2001;11(1):75-81
  • Ives NJ, Stowe RL, Lorigan P, Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol 2007;25(34):5426-34
  • Legha SS, Ring S, Eton O, et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998;16(5):1752-9
  • De Braud F, Khayat D, Kroon BB, et al. Malignant melanoma. Crit Rev Oncol Hematol 2003;47(1):35-63
  • Van Der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254(5038):1643-7
  • Boon T, Coulie P, Marchand M, et al. Genes coding for tumor rejection antigens: perspectives for specific immunotherapy. Important Adv Oncol 1994;53-69
  • Boon T, Van Der BP. Human tumor antigens recognized by T lymphocytes. J Exp Med 1996;183(3):725-9
  • Van Den Eynde BJ, Van Der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol 1997;9(5):684-93
  • Old LJ, Chen YT. New paths in human cancer serology. J Exp Med 1998;187(8):1163-7
  • Sahin U, Tureci O, Schmitt H, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995;92(25):11810-3
  • Boel P, Wildmann C, Sensi ML, et al. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 1995;2(2):167-75
  • Chomez P, De BO, Bertrand M, et al. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res 2001;61(14):5544-51
  • De Plaen E, Arden K, Traversari C, et al. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 1994;40(5):360-9
  • Haas GG Jr, D'Cruz OJ, De Bault LE. Distribution of human leukocyte antigen-ABC and -D/DR antigens in the unfixed human testis. Am J Reprod Immunol Microbiol 1988;18(2):47-51
  • Nelson PT, Zhang PJ, Spagnoli GC, et al. Cancer/testis (CT) antigens are expressed in fetal ovary. Cancer Immun 2007;7:1
  • Brasseur F, Marchand M, Vanwijck R, et al. Human gene MAGE-1, which codes for a tumor-rejection antigen, is expressed by some breast tumors. Int J Cancer 1992;52(5):839-41
  • Brasseur F, Rimoldi D, Lienard D, et al. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 1995;63(3):375-80
  • Weynants P, Lethe B, Brasseur F, et al. Expression of mage genes by non-small-cell lung carcinomas. Int J Cancer 1994;56(6):826-9
  • Bredenbeck A, Losch FO, Sharav T, et al. Identification of noncanonical melanoma-associated T cell epitopes for cancer immunotherapy. J Immunol 2005;174(11):6716-24
  • Miyagawa N, Kono K, Mimura K, et al. A newly identified MAGE-3-derived, HLA-A24-restricted peptide is naturally processed and presented as a CTL epitope on MAGE-3-expressing gastrointestinal cancer cells. Oncology 2006;70(1):54-62
  • Miyahara Y, Naota H, Wang L, et al. Determination of cellularly processed HLA-A2402-restricted novel CTL epitopes derived from two cancer germ line genes, MAGE-A4 and SAGE. Clin Cancer Res 2005;11(15):5581-9
  • Pascolo S, Schirle M, Guckel B, et al. A MAGE-A1 HLA-A A*0201 epitope identified by mass spectrometry. Cancer Res 2001;61(10):4072-7
  • Schultz ES, Lethe B, Cambiaso CL, et al. A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes. Cancer Res 2000;60(22):6272-5
  • Schultz ES, Zhang Y, Knowles R, et al. A MAGE-3 peptide recognized on HLA-B35 and HLA-A1 by cytolytic T lymphocytes. Tissue Antigens 2001;57(2):103-9
  • Tatsumi T, Kierstead LS, Ranieri E, et al. MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma. Clin Cancer Res 2003;9(3):947-54
  • Valmori D, Dutoit V, Rubio-Godoy V, et al. Frequent cytolytic T-cell responses to peptide MAGE-A10(254-262) in melanoma. Cancer Res 2001;61(2):509-12
  • Wang XF, Cohen WM, Castelli FA, et al. Selective identification of HLA-DP4 binding T cell epitopes encoded by the MAGE-A gene family. Cancer Immunol Immunother 2007;56(6):807-18
  • Zhou M, Peng JR, Zhang HG, et al. Identification of two naturally presented MAGE antigenic peptides from a patient with hepatocellular carcinoma by mass spectrometry. Immunol Lett 2005;99(1):113-21
  • Mandruzzato S, Stroobant V, Demotte N, Van Der BP. A human CTL recognizes a caspase-8-derived peptide on autologous HLA-B*3503 molecules and two unrelated peptides on allogeneic HLA-B*3501 molecules. J Immunol 2000;164(8):4130-4
  • Wolfel T, Hauer M, Schneider J, et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995;269(5228):1281-4
  • De Vries TJ, Smeets M, De GR, et al. Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group. J Pathol 2001;193(1):13-20
  • Coulie PG, Brichard V, Van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994;180(1):35-42
  • Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994;91(9):3515-9
  • Robbins PF, El Gamil M, Li YF, et al. Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. J Immunol 1995;154(11):5944-50
  • Doggrell SA. ‘Simply stunning’ – trastuzumab in HER2-positive breast cancer. Expert Opin Pharmacother 2006;7(5):631-4
  • Schuler-Thurner B, Schultz ES, Berger TG, et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 2002;195(10):1279-88
  • Schadendorf D, Ugurel S, Schuler-Thurner B, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 2006;17(4):563-70
  • So-Rosillo R, Small EJ. Sipuleucel-T (APC8015) for prostate cancer. Expert Rev Anticancer Ther 2006;6(9):1163-7
  • Small EJ, Schelhammer PF, Higano CS, et al. Results of a placebo-controlled phase III trial of immunotherapy with APC8015 for patients with hormone refractory prostate cancer (HRPC). ASCO Annual Meeting Proceedings. J Clin Oncol 2005;23(16S Suppl):4500
  • Brichard VG, Gerard C. Melanoma vaccines: achievements and perspectives. Forum (Genova) 2003;13(2):144-54
  • Mitchell MS. Cancer vaccines, a critical review – Part II. Curr Opin Investig Drugs 2002;3(1):150-8
  • Butts C, Murray N, Maksymiuk A, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005;23(27):6674-81
  • Bernhardt SL, Gjertsen MK, Trachsel S, et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study. Br J Cancer 2006;95(11):1474-82
  • Heslop HE, Stevenson FK, Molldrem JJ. Immunotherapy of hematologic malignancy. Hematology Am Soc Hematol Educ Program 2003;):331-49
  • Molldrem JJ, Lee PP, Wang C, et al. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res 1999;59(11):2675-81
  • Molldrem JJ, Lee PP, Kant S, et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Clin Invest 2003;111(5):639-47
  • Brichard VG, Machiels JP, Piperno S, Dorval T. Peptide-based immunization against tumor-specific antigen NA17.A2 in HLA-A2 patients with metastatic cutaneous melanoma. Proc Am Soc Clin Oncol 2001;20(Suppl):1084
  • Cormier JN, Salgaller ML, Prevette T, et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 1997;3(1):37-44
  • Lee P, Wang F, Kuniyoshi J, et al. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J Clin Oncol 2001;19(18):3836-47
  • Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4(3):321-7
  • Markovic SN, Suman VJ, Ingle JN, et al. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization. Am J Clin Oncol 2006;29(4):352-60
  • Fikes JD, Sette A. Design of multi-epitope, analogue-based cancer vaccines. Expert Opin Biol Ther 2003;3(6):985-93
  • Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, et al. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin Cancer Res 2007;13(21):6386-95
  • Bergen M, Chen R, Gonzalez R. Efficacy and safety of HLA-B7/beta-2 microglobulin plasmid DNA/lipid complex (Allovectin-7) in patients with metastatic melanoma. Expert Opin Biol Ther 2003;3(2):377-84
  • Gonzalez R, Hutchins L, Nemunaitis J, et al. Phase 2 trial of Allovectin-7 in advanced metastatic melanoma. Melanoma Res 2006;16(6):521-6
  • Robbins PF, Eggensperger D, Qi CF, Schlom J. Definition of the expression of the human carcinoembryonic antigen and non-specific cross-reacting antigen in human breast and lung carcinomas. Int J Cancer 1993;53(6):892-7
  • Tendler A, Kaufman HL, Kadish AS. Increased carcinoembryonic antigen expression in cervical intraepithelial neoplasia grade 3 and in cervical squamous cell carcinoma. Hum Pathol 2000;31(11):1357-62
  • Petrulio CA, Kaufman HL. Development of the PANVAC-VF vaccine for pancreatic cancer. Expert Rev Vaccines 2006;5(1):9-19
  • Harrop R, Connolly N, Redchenko I, et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res 2006;12(11 Pt 1):3416-24
  • Jungbluth AA, Chen YT, Stockert E, et al. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 2001;92(6):856-60
  • Juretic A, Spagnoli GC, Schultz-Thater E, Sarcevic B. Cancer/testis tumour-associated antigens: immunohistochemical detection with monoclonal antibodies. Lancet Oncol 2003;4(2):104-9
  • Davis ID, Chen W, Jackson H, et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci USA 2004;101(29):10697-702
  • Wang MC, Kuriyama M, Papsidero LD, et al. Prostate antigen of human cancer patients. In: Busch H, Yeoman LC, editors, Methods in cancer research. Volume XIX. Academic Press: New-York, USA; 1982
  • Harada M, Matsueda S, Yao A, et al. Vaccination of cytotoxic T lymphocyte-directed peptides elicited and spread humoral and Th1-type immune responses to prostate-specific antigen protein in a prostate cancer patient. J Immunother 2005;28(4):368-75
  • Madan RA, Gulley JL, Arlen PM. PSA-based vaccines for the treatment of prostate cancer. Expert Rev Vaccines 2006;5(2):199-209
  • Schnurr M, Chen Q, Shin A, et al. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood 2005;105(6):2465-72
  • Baxevanis CN, Voutsas IF, Tsitsilonis OE, et al. Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor. J Immunol 2000;164(7):3902-12
  • Janssen EM, Lemmens EE, Wolfe T, et al. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003;421(6925):852-6
  • Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003;300(5617):337-9
  • Sun JC, Bevan MJ. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 2003;300(5617):339-42
  • Bayry J, Lacroix-Desmazes S, Kazatchkine MD, et al. Modulation of dendritic cell maturation and function by B lymphocytes. J Immunol 2005;175(1):15-20
  • Gaugler B, Van Den EB, Van Der BP, et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994;179(3):921-30
  • Marchand M, Weynants P, Rankin E, et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 1995;63(6):883-5
  • Marchand M, Van Baren N, Weynants P, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999;80(2):219-30
  • Weber JS, Hua FL, Spears L, et al. A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma. J Immunother 1999;22(5):431-40
  • Marchand M, Punt CJ, Aamdal S, et al. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer 2003;39(1):70-7
  • Kruit WH, Van Ojik HH, Brichard VG, et al. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer 2005;117(4):596-604
  • Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 2007;5(7):505-17
  • Atanackovic D, Altorki NK, Stockert E, et al. Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J Immunol 2004;172(5):3289-96
  • Atanackovic D, Altorki NK, Cao Y, et al. Booster vaccination of non-small cell lung cancer (NSCLC) patients with MAGEA3 protein and AS02B adjuvant. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S Suppl):3015
  • Jordan MS, Boesteanu A, Reed AJ, et al. Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat Immunol 2001;2(4):301-6
  • Kohyama M, Sugahara D, Sugiyama S, et al. Inducible costimulator-dependent IL-10 production by regulatory T cells specific for self-antigen. Proc Natl Acad Sci USA 2004;101(12):4192-7
  • Walker LS, Chodos A, Eggena M, et al. Antigen-dependent proliferation of CD4+ CD25+ regulatory T cells in vivo. J Exp Med 2003;198(2):249-58
  • Apostolou I, Von BH. In vivo instruction of suppressor commitment in naive T cells. J Exp Med 2004;199(10):1401-8
  • Kretschmer K, Apostolou I, Hawiger D, et al. Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol 2005;6(12):1219-27
  • Albert ML, Jegathesan M, Darnell RB. Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells. Nat Immunol 2001;2(11):1010-7
  • Huang FP, Platt N, Wykes M, et al. A discrete subpopulation of dendritic cells transports apoptotic intestinal epithelial cells to T cell areas of mesenteric lymph nodes. J Exp Med 2000;191(3):435-44
  • Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Ann Rev Immunol 2003;21:685-711
  • Finkelman FD, Lees A, Birnbaum R, et al. Dendritic cells can present antigen in vivo in a tolerogenic or immunogenic fashion. J Immunol 1996;157(4):1406-14
  • Hawiger D, Inaba K, Dorsett Y, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001;194(6):769-79
  • National Cancer Institute of Canada Clinical Trial Group. Recommendations for Grading of Acute and Subacute Toxicity (Revised version December 1994)
  • Hoos A, Parmiani G, Hege K, et al. A clinical development paradigm for cancer vaccines and related biologics. J Immunother 2007;30(1):1-15.
  • Morse MA, Chui S, Hobeika A, Lyerly HK, Clay T: Recent developments in therapeutic cancer vaccines. Nat Clin Pract Oncol 2005;2(2):108-13
  • Schlom J, Arlen PM, Gulley JL. Cancer vaccines: moving beyond current paradigms. Clin Cancer Res 2007;13(13):3776-82
  • Bolli M, Kocher T, Adamina M, et al. Tissue microarray evaluation of Melanoma antigen E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma. Ann Surg 2002;236(6):785-93
  • Gure AO, Chua R, Williamson B, et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res 2005;11(22):8055-62
  • Gatzemeier U, Pawel JV, Laumen R, et al. Etoposide/vincristine-based chemotherapy with or without carboplatin in extensive-stage small cell lung cancer: a prospective randomized phase III trial. Semin Oncol 1994;21(3 Suppl 6):31-5
  • American cancer society. Cancer facts and figures 2006. Available from: http://www.cancer.org
  • Vansteenkiste J, Zielinski M, Linder A, et al. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II Non-Small Cell Lung Cancer (NSCLC). ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S Suppl):7554
  • Pignon JP, Tribodet H, Scagliotti GV, et al. Lung Adjuvant Cisplatin Evaluation (LACE): a pooled analysis of five randomized clinical trials including 4,584 patients [abstract 7008]. J Clin Oncol 2006;24(Suppl 18S)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.